Cargando…

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelbenegger, Georg, Cacioppo, Filippo, Firbas, Christa, Jilma, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472996/
https://www.ncbi.nlm.nih.gov/pubmed/34579193
http://dx.doi.org/10.3390/vaccines9090956
_version_ 1784574877545529344
author Gelbenegger, Georg
Cacioppo, Filippo
Firbas, Christa
Jilma, Bernd
author_facet Gelbenegger, Georg
Cacioppo, Filippo
Firbas, Christa
Jilma, Bernd
author_sort Gelbenegger, Georg
collection PubMed
description We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis.
format Online
Article
Text
id pubmed-8472996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84729962021-09-28 Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination Gelbenegger, Georg Cacioppo, Filippo Firbas, Christa Jilma, Bernd Vaccines (Basel) Brief Report We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis. MDPI 2021-08-27 /pmc/articles/PMC8472996/ /pubmed/34579193 http://dx.doi.org/10.3390/vaccines9090956 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Gelbenegger, Georg
Cacioppo, Filippo
Firbas, Christa
Jilma, Bernd
Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title_full Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title_fullStr Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title_full_unstemmed Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title_short Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
title_sort rhabdomyolysis following ad26.cov2.s covid-19 vaccination
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472996/
https://www.ncbi.nlm.nih.gov/pubmed/34579193
http://dx.doi.org/10.3390/vaccines9090956
work_keys_str_mv AT gelbeneggergeorg rhabdomyolysisfollowingad26cov2scovid19vaccination
AT cacioppofilippo rhabdomyolysisfollowingad26cov2scovid19vaccination
AT firbaschrista rhabdomyolysisfollowingad26cov2scovid19vaccination
AT jilmabernd rhabdomyolysisfollowingad26cov2scovid19vaccination